BidaskClub cut shares of Oxford Immunotec Global (NASDAQ:OXFD) from a hold rating to a sell rating in a report issued on Saturday morning.

A number of other brokerages also recently weighed in on OXFD. Cowen lowered their price target on Oxford Immunotec Global from $22.00 to $19.00 and set an outperform rating for the company in a report on Thursday, August 17th. BTIG Research started coverage on Oxford Immunotec Global in a report on Thursday, September 28th. They issued a buy rating and a $21.00 price target for the company. Zacks Investment Research upgraded Oxford Immunotec Global from a sell rating to a hold rating in a report on Wednesday, October 4th. ValuEngine downgraded Oxford Immunotec Global from a hold rating to a sell rating in a report on Tuesday, October 31st. Finally, Robert W. Baird reiterated a buy rating and issued a $20.00 price target on shares of Oxford Immunotec Global in a report on Wednesday, November 1st. Three equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The stock has a consensus rating of Hold and an average price target of $19.75.

Shares of Oxford Immunotec Global (NASDAQ:OXFD) opened at $13.24 on Friday. Oxford Immunotec Global has a twelve month low of $12.19 and a twelve month high of $19.51. The company has a current ratio of 4.72, a quick ratio of 4.30 and a debt-to-equity ratio of 0.38.

In related news, Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total transaction of $40,050.00. Following the completion of the transaction, the director now directly owns 17,778 shares in the company, valued at approximately $237,336.30. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Peter Wrighton-Smith sold 55,000 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $16.78, for a total value of $922,900.00. The disclosure for this sale can be found here. 8.11% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the company. Cortina Asset Management LLC grew its stake in shares of Oxford Immunotec Global by 12.8% in the third quarter. Cortina Asset Management LLC now owns 563,290 shares of the company’s stock worth $9,463,000 after purchasing an additional 63,765 shares in the last quarter. Wasatch Advisors Inc. grew its stake in shares of Oxford Immunotec Global by 35.5% in the third quarter. Wasatch Advisors Inc. now owns 574,174 shares of the company’s stock worth $9,646,000 after purchasing an additional 150,343 shares in the last quarter. Teachers Advisors LLC grew its stake in shares of Oxford Immunotec Global by 20.5% in the second quarter. Teachers Advisors LLC now owns 55,674 shares of the company’s stock worth $936,000 after purchasing an additional 9,474 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Oxford Immunotec Global by 13.5% in the second quarter. Bank of New York Mellon Corp now owns 62,566 shares of the company’s stock worth $1,052,000 after purchasing an additional 7,435 shares in the last quarter. Finally, Northern Trust Corp grew its stake in shares of Oxford Immunotec Global by 20.0% in the second quarter. Northern Trust Corp now owns 243,961 shares of the company’s stock worth $4,104,000 after purchasing an additional 40,637 shares in the last quarter. 89.35% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/12/13/oxford-immunotec-global-oxfd-rating-lowered-to-sell-at-bidaskclub.html.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Receive News & Stock Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related stocks with our FREE daily email newsletter.